Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S8DU
|
||||
| Former ID |
DNCL003061
|
||||
| Drug Name |
TGWOOAA
|
||||
| Indication | Generalized anxiety disorder; Social phobia [ICD9: 300, 300.02, 300.23; ICD10:F40-F42, F40.1, F41.1, F93.2] | Phase 2 | [1] | ||
| Company |
Fabre-Kramer Pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | 5-HT 2 receptor | Target Info | Antagonist | [2] | |
| 5-hydroxytryptamine 1A receptor | Target Info | Antagonist | [2] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channelshsa04024:cAMP signaling pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.